Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 8-K (Current Report)
Date of Report: February 3, 2026
Reporting Period: Event-based report for February 3, 2026
BioCardia, Inc., a Delaware corporation, filed this report to disclose a significant clinical development milestone regarding its lead product candidate, CardiAMP Cell Therapy, for the treatment of heart failure.
Key Financial Metrics
This filing is an event-based report (Item 8.01) and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material change disclosed is the acceptance of echocardiography data from the CardiAMP Cell Therapy clinical trial for a Late Breaking Clinical Trial Oral Presentation. This presentation is scheduled for the Technology and Heart Failure Therapeutics (THT) Meeting, taking place March 2-4, 2026, in Boston, Massachusetts.
Guidance, Outlook, and Risks
Outlook: The company anticipates presenting clinical data in March 2026, which may influence investor perception of the CardiAMP therapy's efficacy.
Risks and Contingencies: The filing explicitly states that the information in Item 8.01 and the attached press release (Exhibit 99.1) is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not subject to the liabilities of that section nor incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for specific details on the echocardiography data.
- Confirm the schedule and agenda for the Technology and Heart Failure Therapeutics (THT) Meeting in Boston (March 2-4, 2026).
- Review subsequent filings for the actual presentation results and any impact on the company's clinical development timeline.
- Note that this 8-K does not update the company's financial position; refer to the most recent 10-K or 10-Q for financial health.